CEL-SCI Corporation has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $7,750,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CEL-SCI Corporation is raising $7,750,000.00 in new funding. About CEL-SCI Corporation: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company’s product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
To learn more about CEL-SCI Corporation, visit http://cel-sci.com/
Contact:
Geert Kersten, Chief Executive Officer
703-506-9460
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.